Bevacizumab in Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Histologically or cytologically proven HCC or alpha-fetoprotein level \> 400 ng/ml together with hypervascular tumor and cirrhosis documented by CT scan or MRI. * HCC not amenable to curative treatment (resection, transplantation, percutaneous ablation) * Presence of at least one dimensionally measurable target lesion with largest diameter \>= 2 cm. * No previous chemoembolization, no previous radiotherapy * Cancer of the Liver Italian Program (CLIP) score \< 4 * World Health Organization (WHO) performance status of 2 or less * Life expectancy \>= 3 months. * Age \>= 18 years. * Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter; platelet count, at least 75,000 per cubic millimetre; Hemoglobin, at least 8 g/dl) * Adequate liver function (bilirubin, not more than 2 times the upper limit of normal); Adequate renal function (serum creatinine, less than 150 micromol per liter) * Adequate coagulation function * Written informed consent Exclusion Criteria: * Decompensated cirrhosis (Child-Pugh score \> 7) * CLIP score \> 4 * Variceal bleeding during the previous 3 months * Thromboembolic event during the previous 6 months * Medical condition requiring full dose anticoagulation or anti-platelet drugs * Abnormal cardiac function with history of ischemic heart disease in the previous 6 months, uncontrolled hypertension, unstable angina, severe cardiac arrhythmia, * No brain metastasis, No bone metastasis only * Previous or current malignancies at other sites * No concomitant antitumor treatment including tamoxifen or somatostatin analogs * Unstable systemic diseases or active uncontrolled infections. * Patients (male and female) not using effective contraception if of reproductive potential.